CCXI - Churchill Capital Corp XI -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Churchill Capital Corp XI
ChemoCentryx Inc is a biopharmaceutical company. It is engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
IPO Date: December 17, 2025
Sector: Financial Services
Industry: Shell Companies
Market Cap: $718.53M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.34 | 2.36%
Avg Daily Range (30 D): $0.42 | 2.83%
Avg Daily Range (90 D): $0.47 | 3.13%
Institutional Daily Volume
Avg Daily Volume: 1.37M
Avg Daily Volume (30 D): 2.39M
Avg Daily Volume (90 D): 2.31M
Trade Size
Avg Trade Size (Sh.): 173
Avg Trade Size (Sh.) (30 D): 164
Avg Trade Size (Sh.) (90 D): 172
Institutional Trades
Total Institutional Trades: 95
Avg Institutional Trade: $.91M
Avg Institutional Trade (30 D): $.74M
Avg Institutional Trade (90 D): $.9M
Avg Institutional Trade Volume: .07M
Avg Institutional Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $.89M
Avg Closing Trade (30 D): $.58M
Avg Closing Trade (90 D): $.89M
Avg Closing Volume: 51.78K
 
News
Jul 28, 2026 @ 5:30 AM
Humanoid Global Provides Update on Agility Robotic...
Source: Humanoid Global Holdings Corp.
Oct 17, 2022 @ 12:30 PM
ChemoCentryx Announces Presentations at the 2022 A...
Source: ChemoCentryx, Inc.
Oct 6, 2022 @ 1:40 PM
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical...
Source: Zacks Equity Research
Oct 5, 2022 @ 12:30 PM
ChemoCentryx Announces Upcoming Presentations for ...
Source: ChemoCentryx, Inc.
Sep 26, 2022 @ 10:20 AM
Is Invesco Dynamic Biotechnology & Genome ETF (PBE...
Source: Zacks Equity Research
Financials
  TTM Q1 2026 TTM
Basic EPS
Diluted EPS
Revenue $37.28M
Gross Profit
Net Income / Loss $-134.68M $3.17M $-133.09M
Operating Income / Loss $-39.77M $-.37M $-131.66M
Cost of Revenue
Net Cash Flow $-.33M $-32.81M
PE Ratio